Bone marrow fibrosis at diagnosis is associated with TP53 overexpression and adverse prognosis in low-risk myelodysplastic syndrome.
Department of Surgery, University Hospital Water Cantídio, Federal University of Ceará, Fortaleza, Brazil.
Fernando B
FB
Duarte
Research Laboratory in Haemoglobinopathies and Genetics of Haematological Diseases, Federal University of Ceará, Fortaleza, Brazil.
Maritza C
0000-0001-8980-5638
MC
Barbosa
Research Laboratory in Haemoglobinopathies and Genetics of Haematological Diseases, Federal University of Ceará, Fortaleza, Brazil.
Talyta E
TE
Jesus Dos Santos
Research Laboratory in Haemoglobinopathies and Genetics of Haematological Diseases, Federal University of Ceará, Fortaleza, Brazil.
Romélia P G
0000-0003-3178-412X
RPG
Lemes
Haematology Service of Walter Cantídio University Hospital, Fortaleza, Brazil.
João P
JP
Vasconcelos
Department of Surgery, Federal University of Ceará, Fortaleza, Brazil.
Paulo R L
PRL
de Vasconcelos
Department of Surgery, Federal University of Ceará, Fortaleza, Brazil.
Francisco D
FD
Rocha
Cellular Therapy Center of Porto Alegre, Center for Experimental Research, Porto Alegre, Rio Grande do Sul, Brazil.
Ilana
I
Zalcberg
Cellular Therapy Center of Porto Alegre, Center for Experimental Research, Porto Alegre, Rio Grande do Sul, Brazil.
Diego F
DF
Coutinho
D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
TP53; myelodysplastic syndrome; myelofibrosis; prognosis